Literature DB >> 16789469

The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.

Edward F McCarthy1.   

Abstract

In 1891, William B. Coley injected streptococcal organisms into a patient with inoperable cancer. He thought that the infection he produced would have the side effect of shrinking the malignant tumor. He was successful, and this was one of the first examples of immunotherapy. Over the next forty years, as head of the Bone Tumor Service at Memorial Hospital in New York, Coley injected more than 1000 cancer patients with bacteria or bacterial products. These products became known as Coley's Toxins. He and other doctors who used them reported excellent results, especially in bone and soft-tissue sarcomas. Despite his reported good results, Coley's Toxins came under a great deal of criticism because many doctors did not believe his results. This criticism, along with the development of radiation therapy and chemotherapy, caused Coley's Toxins to gradually disappear from use. However, the modern science of immunology has shown that Coley's principles were correct and that some cancers are sensitive to an enhanced immune system. Because research is very active in this field, William B. Coley, a bone sarcoma surgeon, deserves the title "Father of Immunotherapy".

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16789469      PMCID: PMC1888599     

Source DB:  PubMed          Journal:  Iowa Orthop J        ISSN: 1541-5457


  11 in total

Review 1.  Innovations and strategies for the development of anticancer vaccines.

Authors:  R S Chamberlain; H Kaufman
Journal:  Expert Opin Pharmacother       Date:  2000-05       Impact factor: 3.889

2.  Clinical effect of Coley's toxin. II. A seven-year study.

Authors:  B J JOHNSTON; E T NOVALES
Journal:  Cancer Chemother Rep       Date:  1962-08

3.  Coley's toxins in perspective.

Authors:  C O Starnes
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

4.  II. Contribution to the Knowledge of Sarcoma.

Authors:  W B Coley
Journal:  Ann Surg       Date:  1891-09       Impact factor: 12.969

5.  The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

Authors:  W B Coley
Journal:  Clin Orthop Relat Res       Date:  1991-01       Impact factor: 4.176

Review 6.  Fever and cancer in perspective.

Authors:  U Hobohm
Journal:  Cancer Immunol Immunother       Date:  2001-10       Impact factor: 6.968

7.  The Registry of Bone Sarcoma. A history.

Authors:  E F McCarthy
Journal:  Iowa Orthop J       Date:  1995

8.  Dr William Coley and tumour regression: a place in history or in the future.

Authors:  S A Hoption Cann; J P van Netten; C van Netten
Journal:  Postgrad Med J       Date:  2003-12       Impact factor: 2.401

Review 9.  Current status of adoptive immunotherapy of cancer.

Authors:  A E Chang; S Shu
Journal:  Crit Rev Oncol Hematol       Date:  1996-04       Impact factor: 6.312

10.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  208 in total

Review 1.  Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Authors:  Yvonne Paterson; Patrick D Guirnalda; Laurence M Wood
Journal:  Semin Immunol       Date:  2010-03-17       Impact factor: 11.130

2.  Synthetic Biology Medicine and Bacteria-Based Cancer Therapeutics.

Authors:  Jaehyung Lee; Andrew C Keates; Chiang J Li
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Vaccination in the immunotherapy of glioblastoma.

Authors:  Ziren Kong; Yu Wang; Wenbin Ma
Journal:  Hum Vaccin Immunother       Date:  2017-12-11       Impact factor: 3.452

4.  Advances in bacterial cancer therapies using synthetic biology.

Authors:  Tiffany Chien; Anjali Doshi; Tal Danino
Journal:  Curr Opin Syst Biol       Date:  2017-05-23

5.  Immune dysregulation and osteosarcoma: Staphylococcus aureus downregulates TGF-β and heightens the inflammatory signature in human and canine macrophages suppressed by osteosarcoma.

Authors:  Joanne L Tuohy; Jason A Somarelli; Luke B Borst; William C Eward; B Duncan X Lascelles; Jonathan E Fogle
Journal:  Vet Comp Oncol       Date:  2019-10-15       Impact factor: 2.613

6.  Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy.

Authors:  Kevin Van der Jeught; Sandra Van Lint; Kris Thielemans; Karine Breckpot
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 7.  Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.

Authors:  Julia Kravchenko; Emanuela Corsini; Marc A Williams; William Decker; Masoud H Manjili; Takemi Otsuki; Neetu Singh; Faha Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson; Leroy Lowe; H Kim Lyerly
Journal:  Carcinogenesis       Date:  2015-05-22       Impact factor: 4.944

Review 8.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 9.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

Review 10.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.